Susquehanna International Group
ELDN icon

Susquehanna International Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Susquehanna International Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Buy
+248,300
New +$903K ﹤0.01% 8253
2026
Q1 		– Sell
-13,000
Closed -$19.6K – 13381
2025
Q4 		$19.6K Sell
13,000
-29,500
-69% -$70.1K ﹤0.01% 11966
2025
Q3 		$110K Buy
+42,500
New +$124K ﹤0.01% 11504

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Susquehanna International Group's ELDN Position: Q2 2026 in Review

Susquehanna International Group increased its Eledon Pharmaceuticals (ELDN) stake by 129% in Q2 2026, buying an estimated $517K and bringing the position to 252,232 shares worth $994K. The position accounts for ﹤0.01% of the portfolio, ranked #8218.

Susquehanna International Group first reported a position in ELDN in Q4 2014 and has held it in 19 quarters since. The position peaked at $5.38M in Q1 2025. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Susquehanna International Group held 252,232 shares of Eledon Pharmaceuticals worth $994K as of Q2 2026.
  • Susquehanna International Group bought 142,283 Eledon Pharmaceuticals shares in Q2 2026, an estimated $517K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #8218 holding.
  • Susquehanna International Group first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 19 quarters since.
  • Susquehanna International Group's Eledon Pharmaceuticals position peaked at $5.38M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.